We have evaluated the performance of a centrifugal analyzer, specifically designed for hemostasis tests, for methods based on clothng time as measured by light scattering, or based on splitting of chromogenic substrates. The results were compared with those obtained with a semiautomated coagulometer (clotting tests) or with a manually operated photometer (chromogenic tests). In general, the results with the centrifugal analyzer were at least as precise as those of the comparative methods, with greater output and ease of operation. Disadvantages of the instrument are its partial incompatibility with some commercial reagents and the relative rigidity of the operational parameters, which hinder its use for research. 
derived from the measurement of the light scattered by the thromboplastin-plasma mixture during the PT test. For chromogemc tests, the light beam from a halogen lamp is transmitted by an optic fiber to impinge vertically on the cuvette rotor from below. The absorbance is read at 405 nm by a sensor mounted in the measuring chamber cover. The temperature in the reaction zone is maintained at 37 (± 1) #{176}C. The reagents are stored in refrigerated compartments, with continuous magnetic stirring.
Samples. All the tests were performed on plasma from normal subjects, patients with mild to severe congenital or acquired bleeding disorders, and patients with thrombotic syndromes. Some of the patients were being treated with heparin or oral anticoagulants. Blood was collected and prepared as previously described (3). Plasma pooled from 20 normal donors and snap-frozen at -80 #{176}C was used as the reference standard for all the tests. Within-and betweenassay precision was evaluated by testing, 18 times, two plasmas with different activities for PT, three plasmas (normal, heparinized, and hemophilic) for APT1', and three plasmas for fibrinogen: one normal (normal PT ratio and normal fibrinogen) and two abnormal (one plasma with abnormal PT ratio and normal fibrinogen, the other with an abnormal PT ratio and low fibrinogen).
Reagents and comparison assays. We used the rabbit brain thromboplastin, "Manchester Reagent" (MR; Laboratori Baldacci, Pisa, Italy), in the PT and factor VII assays PT and APTT were measured according to the manufacturers' instructions for each instrument. For single-factor assays by the Coag A Mate x 2, we assayed at least three different dilutions of reference and test plasma, calculating potencies by the mathematical method of Ingram (4) after checking for linearity and parallelism. The procedure adopted for the ACL was that recommended by the manufacturer (i.e., three dilutions for the reference plasma, one for the test plasma). The photometric manual techniques for AT III and PLG are well-accepted procedures (5, 6); for testing with ACL, we used the kits recommended by the manufacturer. Table 1 summarizes the precision data for the ACL and other instruments for PT, APT!', and fibrinogen. for PT and APT1', and as percentages of normal activity for individual clotting factors, AT III, and PLG (results for factor VII and VIII were log-transformed). For all the clotting methods except fibrinogen, we compared the results obtained with two instruments and the same reagent ("instrument comparison") or with two instruments and different reagents ("system comparison"). Correlations (r) were highly significant in all instances, ranging from 0.73 to 0.97 in the system comparisons and from 0.97 to 0.99 in the instrument comparisons.
Results and Discussion
In addition to the reagents for which it has been designed,
ACL
could be also used with two widely used commercial PT and APT!' reagents such as MR and GD reagents, although these reagents were more turbid than those recommended by IL for the ACL. However, when samples from patients taking oral anticoagulants or from patients with a PT ratio >2.5 (approximately 40 s) were tested for PT with MB, the ACL was unable in several instances to detect the clot. We have no explanation for this result, which, although it is not encountered when the instrument is used to assay factor VII, limits the use of MR in the ACL.
An important feature of the ACL is its ability to determine fibrinogen concentrations in plasma at the same time as it determines the PT, without additional cost in reagents and procedure. The results obtained with this system correlated well with those with the conventional clotting assay. Moreover, ACL detected one case of aflbrinogenemia but missed one case of dysfibrinogenemia, for which it gave a result (285 mg/dL) closer to that of the immunoassay (310 mg/dL) than to that of the conventional clotting assay (125 mg/dL). There was only one discrepant result in the singlefactor assays, the factor VIII content for one patient with lupus-like anticoagulant being estimated as much lower by the ACL than by the Coag A Mate x 2(87% vs 406%). This underestimation is related to the presence of phospholipid inhibitors, and can be unmasked by testing more dilutions of the patient's plasma and the reference plasma to look for nonparallel dose-response curves (7) . Therefore, the procedure recommended by the manufacturer, of testing only one dilution of a patient's plasma, should not be followed.
The results obtained for AT III and PLG with the ACL and the reagents recommended by the manufacturer correlated with those obtained with commercial reagents and standard photometric methods. However, there was a tendency for ACL to give higher AT III values than the standard photometric method, as demonstrated by the high intercept value. This tendency was particularly evident in five patients with heterozygous congenital deficiency of AT ifi, for whom the mean value with ACL was 67% vs 55% with the standard method; however, the extent of the overestimation was in no case great enough to cause misclassification of the patients as normals. We do not have any definite explanation for this, but because the reagent for AT ifi determination with ACL involves human thrombin and a long incubation period (90 s), heparin cofactor II may have a concurrent inhibitory action against thrombin and lead to the overestimation of AT III (8, 9) . In fact, the method used in our laboratory also involves human thrombin, but with a much shorter incubation period (30 s). If access to the software of the instrument were easier, we might be able to modifr the stored operational parameters and possibly overcome this drawback.
In conclusion, the ACL centrifugal analyzer has such features as high output, easy operation, high precision, and a large panel of clotting and chromogenic assays that make it useful for the large workloads of the routine coagulation laboratory. Its incompatibility with some reagents and the need to follow strictly the specified operational parameters make it rather too rigid for adaptation to research specifications.
